263 related articles for article (PubMed ID: 27506750)
1. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Chan KY; Chang RS; Lau VW; Chan ML; Lai T
Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
[TBL] [Abstract][Full Text] [Related]
2. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
3. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
4. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Schneider I; Kornhuber ME; Hanisch F
J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
[TBL] [Abstract][Full Text] [Related]
5. Treatment in Lambert-Eaton myasthenic syndrome.
Maddison P
Ann N Y Acad Sci; 2012 Dec; 1275():78-84. PubMed ID: 23278581
[TBL] [Abstract][Full Text] [Related]
6. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
7. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Lee MK; Sunwoo IN; Kim SM
J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
[TBL] [Abstract][Full Text] [Related]
9. [A case of Lambert-Eaton myasthenic syndrome with small cell lung cancer, treated with 3,4-diaminopyridine].
Uekita K; Ishida T; Sekine S; Ishii T; Sato S; Sugawara A; Tachihara M; Watanabe K; Kanazawa K; Saito J; Tanino Y; Munakata M
Nihon Kokyuki Gakkai Zasshi; 2009 Jan; 47(1):76-80. PubMed ID: 19198242
[TBL] [Abstract][Full Text] [Related]
10. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Molgó J; Guglielmi JM
Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
[TBL] [Abstract][Full Text] [Related]
11. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
[TBL] [Abstract][Full Text] [Related]
12. [Lambert-Eaton Myasthenic Syndrome associated with vocal cord carcinoma].
Shipley E; Krim E; Deminière C; Lagueny A
Rev Neurol (Paris); 2008 Jan; 164(1):72-6. PubMed ID: 18342060
[TBL] [Abstract][Full Text] [Related]
13. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2005 Apr; (2):CD003279. PubMed ID: 15846654
[TBL] [Abstract][Full Text] [Related]
14. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Sanders DB
Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
[No Abstract] [Full Text] [Related]
15. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
McEvoy KM; Windebank AJ; Daube JR; Low PA
N Engl J Med; 1989 Dec; 321(23):1567-71. PubMed ID: 2555713
[TBL] [Abstract][Full Text] [Related]
16. [Long-term treatment of Lambert-Eaton syndrome by 3, 4 diaminopyridine].
Jost WH; Mielke U; Forrett-Kaminsky MC; Schimrigk K
Rev Neurol (Paris); 1992; 148(12):776-9. PubMed ID: 1303573
[TBL] [Abstract][Full Text] [Related]
17. [A retrospective study of the effects of 3,4-diaminopyridine treatment in Lambert-Eaton myasthenic syndrome].
Naganuma R; Yabe I; Takahashi I; Matsushima M; Kano T; Sasaki H
Rinsho Shinkeigaku; 2018 Feb; 58(2):83-87. PubMed ID: 29386498
[TBL] [Abstract][Full Text] [Related]
18. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Rev Neurol (Paris); 2004 Feb; 160(2):177-80. PubMed ID: 15034474
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
[No Abstract] [Full Text] [Related]
20. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
